The Scope and Challenges of Vesicular Carrier-Mediated Delivery of Docetaxel for the Management of Cancer

Author(s): Charu Misra, Kaisar Raza, Amit Kumar Goyal*

Journal Name: Current Drug Delivery

Volume 17 , Issue 10 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Since the discovery of liposomes, these vesicular carriers have attracted the researchers from all the vistas of the biomedical domain to explore and harness the potential benefits. Many novel drug delivery-based products have been approved by the United States Food and Drug Administration (USFDA) and other federal agencies of the globe, out of which the major share is of the liposomes and related carriers. Taking cognizance of it, the US-FDA has recently come up with ‘Guidance for Industry on Liposome Drug Products’. In cancer management, chemotherapy is the most frequently employed approach which is still not devoid of untoward challenges and side effects. In chemotherapy, the taxanes, esp. Docetaxel shares a huge percentage in the prescription pattern. Also, the first marketed liposomal product was encasing one drug of this category. Henceforth, the present review will highlight the advances in the delivery of taxanes, in particular docetaxel, with an emphasis on the need, success and pharmacoeconomic aspects of such vesicular-carrier mediated docetaxel delivery.

Keywords: Drug delivery, anti-cancer, bioavailability, liposomes, niosomes, chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 10
Year: 2020
Published on: 29 October, 2020
Page: [874 - 884]
Pages: 11
DOI: 10.2174/1567201817666200623121633
Price: $65

Article Metrics

PDF: 16